Tagged with B

Korea Research based Pharmaceutical Industry Since KRPIA’s creation in 1999, what would you say have been its main achievements in the South Korean pharmaceutical landscape? KRPIA’s foremost achievement during its existence has been its contribution to bringing the focus on R&D to the pharmaceutical industry in South Korea. Our member companies spend between 17% and…

BPOM How has the increasing international integration of the Indonesian economy influenced the challenges and transformations the BPOM went through in the past 9 years since its reorganization? The constant changes and upgrades in international standards in the last decade posed strategic choices to our agency. Since then, BPOM chose to…

Basilea You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea in June 2007 I was captivated by its plans to implement commercial operations in different countries to what was a…

Berlin Chemie/Menarini When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and Central Asia. As the CEO of Berlin Chemie for the last seven years, what would you highlight as the main…

Assobiotec Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report dedicated to biotechnologies in Italy, the sector’s turnover reaches approximately 5 billion Euros and represents 0,6% of the global Italian…

Bausch & Lomb Germany With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities that no other company could thanks to its own transformations and special needs. Since Bausch&Lomb changed ownership in 2007, our…

Baxter Italy Following 20 years of a comprehensive experience in diverse fields of the pharmaceutical industry, you entered Baxter in 2000. At the time, the Italian affiliate was already a well established reality, and the company now celebrates its 40th anniversary with four production sites and more than 1000 employees. What have…

Boehringer Ingelheim Indonesia After 20 years experience with Boehringer Ingelheim, what would you say are the main specificities of the Indonesian pharmaceutical industry? Indonesia differs some what from other Asian countries, starting from being a non reimbursement market with a very large population, to people having a small disposable income. Indonesia also has…

IDS Distribution IDS Distribution is part of an Asian, globe spanning Distribution Company. How does being part of a large, regionally specialized player help IDS Distribution in Indonesia? The company’s regional presence is quite strong. When I first began working at IDS Distribution, I wasn’t sure about the right way to grow…

Boryung Pharmaceutical Boryung has a very interesting history, starting as a pharmacy in Seoul and going on to become one of the top 10 pharmaceutical companies in South Korea. What can you tell us, as the founder, about this notable achievement? Boryung just celebrated in 2007 its 50th anniversary, since it was…

Brazil   With its huge market of 186 million people; its current position as the largest pharma market in Latin America, with strong growth projected; the influx of foreign and local investment into its pharma market; its reputation for conducting high-quality clinical research; and its incredible biological diversity, Brazil seems poised…

Pharma Legal Handbook An intro to the legal situation for orphan drugs and rare diseases in Russia. Prepared in association with Lidings, a leading global law firm, this is an extract from The Pharma Legal Handbook: Russia, available to purchase here for GBP 99.     1. What is the definition of Rare Diseases…